DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2022
INDEX
DYRENIUM (triamterene), 690–692
Dyscrasias, 1204
Dysgeusia, angiotensin converting
enzyme inhibitors and, 736
Dyslipidemia, 877
diabetic, 890t
treatment of, 891
drug therapy for, 892–904
secondary causes of, 890t
treatment of
age and, 890
cerebrovascular disease and, 890
gender and, 890
hypertension and, 890
indications for, 890
National Cholesterol Education
Program (NCEP) guidelines
for, 887–889
peripheral vascular disease and,
890
in post-MI patients, 890
in revascularization patients, 890
smoking and, 890
in type 2 diabetes mellitus, 890
DYSMAN (mefenamic cid), 989
Dyspepsia
niacin-related, 900
nonulcer, 1321
Dyspnea, 522–523, 1058–1059
DYSPORT (botulinum toxin type A),
1792
Dystonia, acute, with neuroleptics, 437t
E
E5555, 871, 872
antiplatelet effects, site of action,
868f
Eadie-Hofstee plot, 95
Early afterdepolarization (EAD), 820,
822f, 825
Early distal tubule, 673
EBASTEL (ebastine), 922t
Ebastine, 922t
Ecamsule, 1827
Echinocandins, 1582–1583
Echinococcus, 1448
Echothiophate, for ophthalmic use,
1788
Eclampsia, 1847
Econazole, 1587
for cutaneous fungal infection, 1818
Economic viability, in drug
development, 6
ECP. See Extracorporeal photopheresis
(ECP)
Ecthiophate iodide ophthalmic
solution, 1153t
ED 50
. See Median effective dose (ED 50
)
EDECRIN (ethacrynic acid), 682–684,
683t, 790
Edema
formation of, mechanism of, 696–
698, 698f
kinins and, 931
EDEX (alprostandil), 952
Edinger-Westphal nucleus, 174
Edoxaban, 866
Edrophonium
antiarrhythmic use of, 824t
cholinergic receptors and, 207t
structure of, 243f
Eentacapone, adrenergic receptors and,
207t
Efalizumab
adverse effects and side effects of,
1825
binding site, 1825t
components, 1825t
FDA-approved indications for, 1825t
mechanism of action of, 1825
method of administration, 1825t
pregnancy category, 1825t
for psoriasis, 1825
dosing, 1825t
efficacy, 1825t
mechanism of action of, 1826f
structural class, 1825t
Efavirenz, 1626t
absorption of, 1643
antiviral activity of, 1643
arrhythmias caused by, 832
chemistry of, 1643
distribution of, 1643
drug interactions with, 1643
elimination of, 1643
pharmacokinetics of, 1641t, 1835t
precautions with, 1643
therapeutic uses of, 1643–1644
Effective dose, median (ED 50
), 73, 74f
Effectiveness
demonstration of, to FDA, 9–10
metabolism and, 139–142
Effective refractory period (ERP), 819
Effector domain, of receptors, 51
Efficacy, 44–45
EFFIENT (prasugrel), 870
EFIENT (prasugrel), 870
Eflornithine, 1424–1426
mechanism of action of, 1841
therapeutic uses of, 1841
EGFR. See Epidermal growth factor
receptor (EGFR)
egr-1 oncogene, 730
Eicosanoids, 937–952
biosynthesis of, 937–939
inhibitors of, 941–942
and bone, 951
and cancer, 948
cardiac effects of, 948
cardiovascular effects of, 948–949
catabolism of, 942
central nervous system effects of,
951
endocrine effects of, 951
endogenous
functions of, 946–948
kidneys and, 947–948
platelets and, 946
and gastrointestinal muscle, 950
history of, 937
and immune response, 948
immune response and, 948, 949–950
and inflammation, 948
inflammatory response and, 948,
949–950
mechanism of action of, 942–946
ocular effects of, 950–951
and parturition, 948
parturition and, 948
pharmacological properties of,
942–946
cardiovascular, 946–947
hematologic, 949
and platelets, 949
pulmonary effects of, 947
receptors, 944t
renal effects of, 947–948, 950
and reproduction, 948
reproduction and, 948
and smooth muscle, 950
therapeutic uses of, 951–952
in abortion, 952
for gastric cytoprotection, 952
for glaucoma, 952
for impotence, 952
for maintenance of patent ductus
arteriosus, 952
for primary pulmonary
hypertension, 952
Eicosapentaenoic acid, 937
Elderly, NSAIDs for, 976–977
Electrocardiogram (ECG)
in arrhythmia diagnosis, 823, 825f
impulse propagation and, 818–819
of normal cardiac rhythm, 825f